Matteo Bianchi

Title: Matteo Bianchi: Innovator in Multi-Specific T-Cell Engagers

Introduction

Matteo Bianchi is a prominent inventor based in Schlieren, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of multi-specific proteins for therapeutic applications.

Latest Patents

Matteo Bianchi holds a patent for "DARPin based multi-specific t-cell engagers." This invention relates to recombinant multi-specific proteins that include binding agents with specificity for various targets, such as CD3, CD33, CD123, and CD70. The patent also encompasses nucleic acids encoding these multi-specific proteins, pharmaceutical compositions containing them, and their use in treating or diagnosing diseases, including acute myeloid leukaemia (AML) in mammals, including humans.

Career Highlights

Matteo Bianchi is associated with Molecular Partners AG, a company known for its innovative approaches in the field of protein engineering. His work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.

Collaborations

Matteo collaborates with talented professionals in his field, including Nina Reschke and Sebastian Grimm. Their combined expertise contributes to the ongoing research and development efforts at Molecular Partners AG.

Conclusion

Matteo Bianchi's innovative work in the realm of multi-specific t-cell engagers showcases his commitment to advancing cancer treatment. His contributions are paving the way for new therapeutic options that could significantly impact patient care.